Form 4: Hologic CFO Karleen Oberton Reports Equity Changes

Hologic's Chief Financial Officer, Karleen Oberton, reported recent equity transactions including RSU grants and tax-related share dispositions.

Summary

• Karleen Marie Oberton, Chief Financial Officer of Hologic Inc. (HOLX), reported changes in her beneficial ownership of common stock.
• On November 7, 2025, 9,427 shares of common stock were disposed of at a price of $74.1 per share to cover tax obligations related to the settlement of performance/restricted stock units.
• On November 10, 2025, 43,741 restricted stock units (RSUs) were acquired. These RSUs will vest in equal installments on each of the first three anniversaries of the grant date.
• On November 11, 2025, an additional 1,449 shares of common stock were disposed of at a price of $74.6 per share for tax obligations.
• Following these transactions, Ms. Oberton's direct beneficial ownership of common stock stands at 152,068 shares, which includes 41,121 restricted stock units/performance stock units whose settlement has been deferred.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the significant grant of restricted stock units to the CFO, indicating continued alignment of management's interests with long-term shareholder value. The dispositions were for tax purposes, which is a neutral event.

Positives

• The acquisition of 43,741 restricted stock units on November 10, 2025, indicates continued equity incentive for the Chief Financial Officer.
• The net increase in beneficial ownership from 109,776 shares (after the first disposition) to 152,068 shares (after all reported transactions) reflects an overall increase in the CFO's stake in the company.

Negatives

• Dispositions of 9,427 shares and 1,449 shares were made solely to satisfy tax withholding obligations upon the vesting of equity awards, not as a discretionary sale for profit.

Future Outlook

The restricted stock units granted on November 10, 2025, are scheduled to vest in equal installments on each of the first three anniversaries of the grant date, indicating future equity compensation for the CFO.

Industry Context

This Form 4 filing details routine insider equity transactions for a Chief Financial Officer, which is a standard compensation practice across various industries, including the medical technology sector where Hologic operates. Such filings provide transparency into executive stock ownership and compensation structures.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of executive compensation is a common practice in publicly traded companies, aligning executive interests with shareholder value over the long term.
• The disposition of shares to cover tax obligations upon the vesting of equity awards is a standard and expected event for executives receiving stock-based compensation, consistent with practices observed in companies like Medtronic, Danaher, or Stryker, which also utilize equity compensation.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CFO aligns her incentives with long-term shareholder value. The tax-related dispositions are routine and do not reflect a change in management's confidence.
• Employees: Standard equity compensation practices for executives can set a precedent or reflect the company's overall approach to employee incentives.

Next Steps

• The acquired restricted stock units will vest in equal installments on the first three anniversaries of the November 10, 2025, grant date.

Key Dates

Keywords

Hologic, HOLX, Karleen Oberton, CFO, Form 4, Insider Trading, Equity Transactions, Restricted Stock Units, RSU, Stock Ownership, Tax Withholding